Asteria Health Safety Report — Q2 2026
Q2 2026 headline
F.H. INVESTMENTS, Inc. (dba Asteria Health) reported no new recalls in Q2 2026, marking a clean quarter. The brand has 13 total recalls on record, all from the past 12 months, with no Class I recalls in the last five years. The company currently holds a safety grade of A.
By the numbers
Total recalls on record: 13
Class I recalls in last 5 years: 0
Recalls in Q2 2026: 0
Recalls in the last 12 months: 13
What triggered F.H. INVESTMENTS, Inc. (dba Asteria Health) recalls
All 13 recalls on record stem from one issue: the potential presence of metal particulate matter in sterile pellet medications. This foreign substance contamination affected multiple hormone-based products across different dosages.
Top recall reason:
- Presence of foreign substance — potential presence of metal particulate matter in sterile pellets (13 recalls)
Notable recalls this period
The most recent recalls occurred in late January 2026. Because Q2 2026 saw no new recalls, we review the most recent actions on file:
Testosterone 100mg with Triamcinolone Acetonide 20mcg — Class II recall issued January 26, 2026. The product contained potential metal particulate matter. Patients using this medication should contact their pharmacy or healthcare provider.
Estradiol 37.5mg — Class II recall issued January 26, 2026. Metal particulate contamination was detected in this hormone pellet. Patients should verify their medication lot with their provider.
Estradiol 12.5mg — Class II recall issued January 26, 2026. This product also carried the risk of metal particulate matter in the sterile pellet formulation.
All three recalls are Class II, meaning the contamination poses a potential health risk but is unlikely to cause serious injury. If you or a family member uses Asteria Health hormone pellets, check your medication lot number against the recall list.
Trend analysis
F.H. INVESTMENTS, Inc. (dba Asteria Health) experienced a significant recall event in January 2026 that affected 13 products. All recalls stem from a single manufacturing or quality control issue: metal particulate contamination in sterile pellets. The fact that Q2 2026 brought no new recalls suggests the company may have addressed the root cause.
However, the concentration of 13 recalls in a short window indicates a serious quality problem that required swift action. The absence of Class I recalls (the most dangerous category) is a positive sign. Moving forward, whether F.H. INVESTMENTS, Inc. (dba Asteria Health) is safe depends on whether the company's corrective measures hold. One clean quarter is encouraging but not yet a long-term trend.
What it means for shoppers
If you use Asteria Health hormone pellets, do not panic. All recent recalls are Class II, and the company acted to notify patients and healthcare providers. Check your medication bottle for the lot number and cross-reference it with the recall notices. Your pharmacist or doctor can tell you whether your specific medication is affected.
The good news: Q2 2026 was recall-free, and the company holds a safety grade of A. This suggests corrective action may be working. The caution: a cluster of recalls in early 2026 shows quality control lapses did occur. Continue to use the product as prescribed, but stay informed about any future notices.
If you have concerns about your medication, contact your healthcare provider. Do not stop taking prescribed medication without medical guidance.
Stay ahead of F.H. INVESTMENTS, Inc. (dba Asteria Health) recalls
Recall Watch monitors F.H. INVESTMENTS, Inc. (dba Asteria Health) and thousands of other brands for safety issues. To get personalized alerts whenever a new recall affects products you use, set up free brand-specific alerts →. You can also see F.H. INVESTMENTS, Inc. (dba Asteria Health)'s full recall history → anytime.